


Technology Advisory Committee C Interests Register


Topic: Zanubrutinib for treating chronic lymphocytic leukaemia [ID5078]

Publication Date: 22 November 2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	Committee member	Indirect - financial	Mr Chambers has participated in an advisory panel for Pfizer (comparator company) in an unrelated disease area (prostate cancer) and has provided advice on economic modelling to Sanofi (comparator company) in an unrelated disease area (COPD).	21.06.2023	It was agreed that his declaration would not prevent Mr Chambers from participating in discussions for this appraisal.
Elizabeth Thurgar	Committee member	Indirect - financial	Ms Thurgar has worked with AstraZeneca (comparator company) in unrelated indications (hyperkalemia and CKD).	21.06.2023	It was agreed that her declaration would not prevent Ms Thurgar from participating in discussions for this appraisal.
Dr Richard Nicholas	Committee member	Indirect - financial	Dr Nicholas has attended paid advisory boards with Roche (comparator company) for an unrelated condition (multiple sclerosis).	26.06.2023	It was agreed that his declaration would not prevent Dr Nicholas from participating in discussions for this appraisal.
Dr Steven Lloyd	Committee member	Non-Financial professional interests	Dr Lloyd has undertaken advisory work for comparator companies Pfizer and AbbVie in unrelated areas around vaccinations and women's health.	22.08.2023	It was agreed that his declarations would not prevent Dr Lloyd from participating in discussions for this appraisal.
Dr Rosalynd Johnston	Clinical expert	Direct and indirect - financial	Dr Johnston attended a meeting and fulfilled a paid speaking engagement for	18.11.2022	It was agreed that her declarations would not prevent Dr Johnston



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			comparator company AbbVie in January 2023.		from providing expert advice to the committee.
			Dr Johnston attended a meeting in April 2023 which was funded by the manufacturer BeiGene where an invited group of UK CLL specialist doctors and scientists met to discuss future research and has received financial support from Abbvie to attend the ICML Conference in June 2023.	06.06.2023	
			Dr Johnston also noted that her nominating organisation, the UK CLL Forum, has received funding from the manufacturer BeiGene and comparator companies AbbVie, AstraZeneca, Janssen and Roche.	10.07.2023	
			Dr Johnston attended an Ad board for BeiGene in August 2023.	04.09.2023	
Professor Francesco Forconi	Clinical Expert	Direct and indirect - financial	Professor Forconi has participated in an advisory board for BeiGene. Professor Forconi has received honoraria, speaker bureau fees and travel and accommodation fees from AbbVie, Janssen-Cilag, BeiGene and AstraZeneca.	21.11.2023 05.07.2023	It was agreed that his declarations would not prevent Professor Forconi from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Nick York	Patient expert	Indirect - financial	Mr York is employed as a Patient Advocate by his nominating organisation Leukaemia Care, which has received funding and honoraria from comparator companies AbbVie, AstraZeneca, Gilead, Janssen and Pfizer.	02.03.2023	It was agreed that his declarations would not prevent Mr York from providing expert advice to the committee.